| dc.contributor.author | Kusuma, Bhaskar Reddy | |
| dc.contributor.author | Brandt, Gary E. L. | |
| dc.contributor.author | Blagg, Brian S. J. | |
| dc.date.accessioned | 2017-03-28T18:06:05Z | |
| dc.date.available | 2017-03-28T18:06:05Z | |
| dc.date.issued | 2012-12-21 | |
| dc.identifier.citation | Kusuma, B. R., Brandt, G. E. L., & Blagg, B. S. J. (2012). Synthesis of Cruentaren A. Organic Letters, 14(24), 6242–6245. http://doi.org/10.1021/ol302999v | en_US |
| dc.identifier.uri | http://hdl.handle.net/1808/23500 | |
| dc.description.abstract | Cruentaren A, an antifungal benzolactone produced by the myxobacterium Byssovorax cruenta, is highly cytotoxic against various human cancer cell lines and a highly selective inhibitor of mitochondrial F-ATPase. A convergent and efficient synthesis of cruentaren A is reported, based upon a diastereoselective alkylation, a series of stereoselective aldol reactions utilizing Myers’ pseudoephedrine propionamide, an acyl bromide–mediated esterification and a ring-closing metathesis (RCM) as the key steps. The RCM reaction was applied for the first time towards the total synthesis of cruentaren A, which led to a convergent and efficient synthesis of the natural product. | en_US |
| dc.publisher | American Chemical Society | en_US |
| dc.rights | This document is the Accepted Manuscript version of a Published Work that appeared in final form in Organic Letters, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://dx.doi.org/10.1021/ol302999v. | en_US |
| dc.title | Synthesis of Cruentaren A | en_US |
| dc.type | Article | en_US |
| kusw.kuauthor | Kusuma, Bhaskar Reddy | |
| kusw.kuauthor | Brandt, Gary E. L. | |
| kusw.kuauthor | Blagg, Brain S. J. | |
| kusw.kudepartment | Chemistry | en_US |
| kusw.oanotes | Per SHERPA/RoMEO 3/28/2017: Author's Pre-print: grey tick subject to Restrictions below, author can archive pre-print (ie pre-refereeing)
Restrictions: Must obtain written permission from Editor
Must not violate ACS ethical GuidelinesAuthor's Post-print: grey tick subject to Restrictions below, author can archive post-print (ie final draft post-refereeing)
Restrictions: If mandated by funding agency or employer/ institution
If mandated to deposit before 12 months, must obtain waiver from Institution/Funding agency or use AuthorChoice
12 months embargoPublisher's Version/PDF: cross author cannot archive publisher's version/PDF
General Conditions: On author's personal website, pre-print servers, institutional website, institutional repositories or subject repositories
Non-Commercial
Must be accompanied by set statement (see policy)
Must link to publisher version
Publisher's version/PDF cannot be used | en_US |
| dc.identifier.doi | 10.1021/ol302999v | en_US |
| kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
| kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
| dc.rights.accessrights | openAccess | |
